-transparent.png){kind=logo}
Sotalol (Sotalex), 320 or 960 mg, was administered to 12 healthy subjects daily for a period of four days in a double-blind trial over 11 days. The effects of sotalol on heart rate, blood pressure, EEG, subjective quality of sleep, polygraphically determined sleep pattern, and psychophysiological parameters such as psychomotor performance, memory, perception, vigilance, and general condition were studied and were related to dosage and plasma levels. Steady-state plasma levels of sotalol were reached within 24 hours after a single dose; 960 mg resulted in plasma levels three times higher than those reached with 320 mg, which indicates first-order linear absorption. The effects of sotalol on EEG, sleep, and performance in psychological tests were equivocal and do not yield evidence for CNS activity of sotalol.
W Bender, and
W Greil, and
E Rüther, and
K Schnelle
January 1977,
Acta medica Scandinavica. Supplementum,
W Bender, and
W Greil, and
E Rüther, and
K Schnelle
January 1979,
Journal of clinical pharmacology,
W Bender, and
W Greil, and
E Rüther, and
K Schnelle
October 1984,
Archives internationales de pharmacodynamie et de therapie,
W Bender, and
W Greil, and
E Rüther, and
K Schnelle
August 1976,
British journal of clinical pharmacology,
W Bender, and
W Greil, and
E Rüther, and
K Schnelle
June 1985,
British journal of clinical practice. Supplement,
W Bender, and
W Greil, and
E Rüther, and
K Schnelle
March 1979,
British journal of pharmacology,
W Bender, and
W Greil, and
E Rüther, and
K Schnelle
January 1982,
Therapie,
W Bender, and
W Greil, and
E Rüther, and
K Schnelle
August 1968,
The American journal of cardiology,
W Bender, and
W Greil, and
E Rüther, and
K Schnelle
November 1975,
Experientia,
W Bender, and
W Greil, and
E Rüther, and
K Schnelle
February 1987,
Archives internationales de pharmacodynamie et de therapie,
